In this work, we summarize a comprehensive spectrum of SEC23B variants, describe nine new CDA II cases accounting for six previously unreported variants, and discuss innovative therapeutic approaches for CDA II. Here, SEC23B is linked to Congenital dyserythropoietic anemia type II.